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Cognitive-Behavioural Therapy for Patients with Schizo-
phrenia: A Multicenter Randomised Controlled Trial in Bei-
jing, China 
 
Abstract 
Background: Meta-analyses support the efficacy of cognitive-behavioural therapy (CBT) for 
schizophrenia in western cultures. 
Aims: To compare the efficacy of CBT and Supportive Therapy (ST) for patients with schiz-
ophrenia in China. 
Method: A multicenter randomized controlled, single-blinded, parallel group trial enrolled a 
sample of 192 patients with schizophrenia. All patients were offered 15 sessions of either 
CBT or ST over 24 weeks and followed up for additional 60 weeks. 
Results: Effect size analysis showed that patients who had received CBT showed rapid im-
provements in all symptoms as measured by PANSS, insight and social functioning in the 
first 12 week and 24 weeks and maintained the improvement over the course of the study to 
week 84. Patients in the CBT group also showed significantly greater and more durable im-
provement in the total score of PANSS (P= 0.045; between group d=0.48), positive symp-
toms (P = 0.018; between group d=0.42), insight, and social functioning (P= 0.037; between 
group d=0.64).  
Conclusions: CBT was superior to ST in improving the total score of PANSS, positive symp-
toms, insight and social functioning of patients with schizophrenia in China.  
Declaration of interest: None. 
Key words: cognitive behavioural therapy, supportive therapy, schizophrenia, Randomised 
Controlled Trial, China. 
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Cognitive-behavioural therapy for patients with schizophrenia: a 
multicentre randomised controlled trial in Beijing, China 
 
Introduction 
Schizophrenia is a chronic, severe and dis-
abling mental disorder. However, the po-
tential for recovery is increasingly being 
recognised. Schizophrenia affects approx-
imately 0.7% of people at some point in 
their lives in China.1 This translates to ap-
proximately five million people suffering 
from schizophrenia in China, representing 
over 20% of the total 24 million people 
suffering from the disorder worldwide.1 
 The primary treatment for schizo-
phrenia continues to be pharmacological 
(National Institute for Clinical Excellence 
2003.). However, long-term therapy using 
pharmacology is associated with a range of 
adverse effects, including a high rate of 
poor medication adherence (Velligan et al. 
2006). Pharmacological treatment is lim-
ited in improving clinical, personal and so-
cial functioning and patients often have a 
high risk of relapse (Freeman et al. 1998; 
A. K. Morrison 2009; A. P. Morrison et al. 
2011; Rathod et al. 2008; Tarrier et al. 
2004). Certain psychosocial treatments, 
such as cognitive behaviour therapy 
(CBT) , have been shown to have a benefi-
cial effect on positive and negative symp-
toms, mood, social functioning and social 
anxiety and is effective in reducing read-
missions to hospital, duration of admission 
and symptom severity (Lysaker et al. 
2010), (Wykes et al. 2008). CBT therefore 
addresses the limitations of medication-
based treatment. 
CBT is a well-established standard 
psychotherapy used in western clinical 
practice as an adjunct treatment for schizo-
phrenia (National Institute for Clinical 
Excellence 2003.). CBT has been recom-
mended as standard treatment for people 
with schizophrenia in Western countries. 
The guidelines for its use have been pro-
vided by the National Institute for Health 
and Clinical Excellence(NICE 2009) and 
the Schizophrenia Patient Outcomes Re-
search Team (Kreyenbuhl et al. 2010).  
When using CBT as a treatment for 
schizophrenia, studies focused on address-
ing positive and negative symptoms, mood, 
social functioning and social anxiety 
(Wykes et al. 2008). For example, Drury et 
al.  showed that CBT reduced positive 
symptoms at a faster rate during the first 12 
weeks following hospital admission(Drury 
et al. 2000). Positive symptoms were re-
duced during this time compared to those 
patients who did not receive the CBT 
treatment. Drury et al. (Drury et al. 2000) 
also found more rapid improvement in clin-
ical recovery as indicated by increased in-
sight, less dysphoria and ‘low level’ psy-
chotic thinking and less disinhibition.  
Emerging evidence indicates deficits in 
social functioning are prominent in patients 
with schizophrenia; their symptoms and 
cognitive functioning are predictive of their 
level of social functioning (Apiquian et al. 
2009; Brissos et al. 2012). DSM-IV-TR 
acknowledges that assessing social function-
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ing is important in the antipsychotic treat-
ment of schizophrenia(American Psychiatric 
Association DSM-IV-TR 2000). Conse-
quently, social functioning is an important 
measure of the effectiveness of psycho so-
cial treatment for schizophrenia (Burns and 
Patrick 2007). 
Insight is another important outcome 
indicator that needs to be considered. Insight 
is defined as ‘a patient’s recognition of hav-
ing a psychiatric disorder, of the social con-
sequences of that disorder and of the need 
for treatment’(Wang et al. 2011).  It is there-
fore critical for compliant behaviour and 
engaging patients in a treatment process 
(Rathod et al. 2008). Insight has recently 
become a major consideration in pharma-
cotherapy and psychosocial intervention in 
schizophrenia. Therefore, when examining 
the effectiveness of CBT treatment it is im-
portant to assess insight and its improve-
ment.  
CBT employs a number of strategies, 
such as a therapeutic alliance marked by 
collaboration on a problem list, normalisa-
tion of the psychotic experience and modifi-
cation of dysfunctional cognitions and be-
haviours(Warman and Beck 2003). CBT al-
so teaches and enhances personal coping 
strategies that allow patients to manage their 
symptoms and daily difficulties. The CBT 
approach may become the standard ap-
proach to schizophrenia, leading to multiple 
improved outcomes—not only does it re-
duce positive and negative symptoms, it also 
improves cognitive insight about the illness 
and the personal and social functioning of 
patients.  
However, most published studies con-
tain a lack of methodological rigour, either 
in their small sample sizes or in the short 
term of interventions. No studies compre-
hensively assess the effectiveness of using 
the CBT approach on the negative symp-
toms, positive symptoms, disorganization 
symptoms, excitement and emotional dis-
tres as well as insight and social function-
ing. Most importantly, there is no robust 
evidence indicating that using CBT to treat 
schizophrenia is effective for Chinese pa-
tients suffering from schizophrenia. To fill 
in these research gaps, this study sought to 
examine the efficacy of CBT over and 
above the effects of other psychosocial ap-
proaches by using a multicentre based ran-
domised controlled trial in a large clinical 
sample. This study aimed to comprehen-
sively assess the effectiveness of the CBT 
approach in improving not only negative 
symptoms, positive symptoms, disorgani-
zation symptoms, excitement and emotion-
al distress, but also insight and social func-
tioning, which are the important function-
ing areas of schizophrenia. The hypothesis 
asserts that the CBT approach is effective 
and has a beneficial effect on positive and 
negative symptoms, disorganization symp-
toms, excitement and emotional distress, as 
well as insight and social functioning in 
Chinese schizophrenia patients. 
 
Methods 
Participants  
This study was conducted at three special-
ised psychiatric hospitals in Beijing, China. 
Patients were recruited from inpatient units 
or outpatient departments. Eligible partici-
pants met the following inclusion criteria: 
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aged between 18–60 years; diagnosed with 
schizophrenia through a Structured Clinical 
Interview for DSM-IV Axis I Disorders-
Clinician Version17 by raters who were 
well-trained research psychiatrists (intra-
class correlation >0.80); had a total score 
of 60 or above on the Positive and Nega-
tive Syndrome Scale (PANSS) which indi-
cated severe symptom burden; on an ade-
quate dose of an antipsychotic for at least 
the past four weeks of treatment; capable 
of providing informed consent. 
An adequate dose of antipsychotic 
medication was defined as regular use of 
antipsychotic medication with good adher-
ence, at or above the equivalent of 300 mg 
daily of chlorpromazine, including a mini-
mum period of at least two weeks of treat-
ment with the equivalent of 600 mg of 
chlorpromazine. Participants were exclud-
ed if they met the following exclusion cri-
teria: a comorbid diagnosis of mental retar-
dation or primary substance dependence; a 
score of five or more of conceptual disor-
ganisation according to PANSS, which in-
cluded those who could not communicate, 
had poor rapport, or lack of spontaneity 
and flow of conversation; had received 
electroconvulsive therapy (ECT) within the 
past six months prior to entry into the 
study; currently receiving other types of 
systematic psychotherapy. Fig. 1 is the 
CONSORT diagram for the trial. 
 
Sample size calculation 
The sample size calculation was based on a 
previous randomised controlled trial of a 
similar design in the UK, which resulted in 
a recovery rate of 63% in the CBT group 
compared to 39% in the befriending group 
(recovery was defined as having a 50% or 
greater reduction in total scores of the 
Comprehensive Psychopathological Rating 
Scale by the end of treatment) (Sensky et 
al. 2000). Based on the difference between 
the two treatment groups of this trial, 80 
patients across the two groups were re-
quired to achieve an alpha-value of 0.05 
and a power of 80%. Assuming a 20% 
drop-out rate, a minimum sample of 96 pa-
tients was required for each group. 
 
Procedures 
Participants deemed eligible for the trial 
were randomly allocated to the CBT group 
and the ST group (1:1 randomisation). 
Block randomisation was conducted by 
computer-generated, random numbers to 
allocate the eligible participants to either of 
the two groups, stratified according to 
study site and performed at a geographical-
ly remote and independent location. The 
trial lasted for 84 weeks, with patients re-
ceiving 15 sessions of either CBT or ST 
over a 24-week period followed by 60 
weeks of follow-up. 
 
Interventions 
Medications 
Medication prescription was not affected or 
influenced by the trial protocol. The pa-
tients in both groups remained under their 
usual psychiatric care. The types or dose of 
medications were decided or adjusted by 
their primary treating teams based on clini-
cal needs. The doses of antipsychotic med-
ication were recorded and converted into 
equivalent doses of chlorpromazine dose 
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(Sim et al. 2004). 
 
 
Cognitive-behavioural therapy 
CBT is a manual-based treatment. In this 
study, it was delivered by therapists to pa-
tients who were allocated to the CBT 
group. There were 12 sessions in the first 
12 weeks followed by three consolidated 
sessions in the subsequent 12 weeks. Each 
session lasted for about 50 minutes but 
flexibility on time was permitted depend-
ing on the attention, tolerance level and 
mental state of the participants. 
The trial protocol for using CBT to 
treat schizophrenia was compiled in Chi-
nese and based on the principles and prac-
tice developed by Kingdon and Turkington 
(Kingdon and Turkington 2004). This train-
ing manual was written in Chinese and 
translated to English before it was used as 
the training material for review by Kingdon 
and Turkington, and three CBT specialists 
in Hong Kong, Beijing and Changsha of 
China. Its cultural relevance and accepta-
bility was tested on ten patients with schiz-
ophrenia. 
The first four sessions were delivered 
twice a week and focused on the introduc-
tion of the treatment, building a therapeutic 
alliance based on collaboration on a prob-
lem list, psycho-education about the cogni-
tive-behavioural model of psychosis and 
normalisation of the experience of psycho-
sis. A cognitive formulation was developed 
to make sense of psychotic experiences. 
The next six sessions in the intermediate 
stage were offered once a week. These ses-
sions involved teaching coping strategies 
and cognitive-behavioural work with delu-
sions, hallucinations and negative symp-
toms. Homework was also assigned in a 
flexible manner after each session to con-
solidate what was learnt in the session. The 
two sessions in the final phase were deliv-
ered once every two weeks, including a 
discussion of attitudes to medication and 
relapse prevention work. Finally, three 
booster sessions were offered once month-
ly for reviewing progress and consolidating 
what patients had learnt of CBT strategies 
for coping with future problems related to 
the recurrence of psychotic symptoms. 
 
Supportive therapy 
Supportive therapy was also in the form of 
manual-based treatment and comprised 12 
sessions in the first 12 weeks followed by 
three consolidated sessions in the subse-
quent 12 weeks. Each session lasted for 
about 50 minutes. This intervention was 
based on supportive models of psychother-
apy and was the most widely practiced 
form of individual psychotherapy in psy-
chiatric services (Winston et al. 2004). The 
primary goal of the ST in the first 12 ses-
sions was to provide patients with emo-
tional support, knowledge of mental disor-
ders, and provide suggestions to patients on 
preventing a relapse of the disease. Similar 
to the CBT approach, ST also focused on 
developing and maintaining therapeutic 
alliance and providing psycho-education to 
patients. However, ST did nothave a prob-
lem list to work on, did not develop coping 
strategies, did not have a cognitive formu-
lation or reality testing of paranoia and 
voices. For example, patients could select 
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session topics such as discussing interests, 
personal experiences, and expressing feel-
ings. Therapists were nondirective but used 
reflective listening and summarising tech-
niques to support patients in coping with 
current life events and in relapse preven-
tion. No homework was given and no spe-
cific CBT techniques were used in ST.  
 
Trial therapists 
The eight therapists were experienced psy-
chiatrists or psychologists with five to 20 
years’ experience using psychotherapy in 
hospitals on patients with a mental disor-
der. They had been trained and supervised 
in the application of cognitive therapy for 
psychosis by experienced cognitive behav-
ioural therapists, and had special expertise 
in the application of CBT for psychosis 
using a translated Kingdon and Turkington 
manual (DK, DT and RN).20 The on-site 
training courses of CBT for schizophrenia 
lasted more than 100 hours throughout the 
trial period, including didactic teaching, 
case presentation, in-vivo demonstration of 
skills and role-play. After the training 
courses, the eight therapists also participat-
ed in peer supervision using role-play and 
listening to other therapists’ treatment tape 
recordings in biweekly consultation meet-
ings. Their treatment sessions were moni-
tored and reviewed by Kingdon via video 
conference once a week.  
 
Supervision 
Psychotherapy was supervised in three 
ways: peer supervision, expert supervision 
in CBT, and consultation on culturally-
related issues.   
During peer supervision, the therapist 
presented the case formulation, treatment 
plan and therapy progress for every CBT 
case during the first six sessions. The peer 
therapists also provided feedback and sug-
gestions and selected sections of the indi-
vidual case’s session recordings for super-
vision. Supervision for ST also occurred 
for each participant focusing on the use of 
supportive methods and differentiating 
these from CBT. 
In this study, expert supervision was 
provided for CBT only. Therapists submit-
ted written case reports, case formulations, 
treatment plans, therapy processes and 
team members’ questions about the cases 
arising from the peer supervision sessions 
to the second author. These submissions 
occurred once every two weeks throughout 
the intervention period. Supervision was 
delivered once every two weeks by an ex-
pert therapist in CBT for psychosis (DK) 
from the United Kingdom via phone, 
Skype or email. The principal investigator 
(ZJL), a consultant psychiatrist with specif-
ic knowledge of CBT techniques and cul-
ture related problems, also provided face-
to-face supervision for all trial therapists on 
a monthly basis.  
 
Ethical issues 
The study protocol was approved by the 
Beijing Municipal Science & Technology 
Commission. The study was also approved 
by the IRB of participating hospitals, the 
Research & Ethics Committee of Beijing 
Anding Hospital, Beijing Huilongguan 
Hospital and The Sixth Hospital of Peking 
University. The protocol was explained 
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clearly and all the study participants signed 
informed consent forms before the baseline 
assessments were commenced. A partici-
pant could withdraw from the trial at any 
stage and this did not affect their clinical 
care. 
 
Measures 
Three outcomes—severity of psycho-
pathology, insight and social functioning—
were assessed by standardised measures 
through clinical interviews administered by 
the clinicians.  
Severity of psychopathology  
Severity of psychopathology was assessed 
according to the Chinese version of the 
Positive and Negative Syndrome Scale 
(PANSS) (Si et al. 2004). PANSS scores 
were calculated using five dimensions: 
positive symptoms, negative symptoms, 
disorganisation symptoms, excitement and 
emotional distress (van der Gaag et al. 
2006). The PANSS includes 30 items, each 
of which is scored on a seven point Likert 
scale (1 = absence of psychopathology; 7 = 
very severe symptom). PANSS has demon-
strated good psychometric properties with 
Cronbach’s alphas of 0.73, 0.83 and 0.79 
for positive, negative and GPS symptoms 
respectively (Kay et al. 1988). The reliabil-
ity and validity of the scale for Chinese pa-
tients with schizophrenia was excellent. 
The internal consistency with Chrobach’s 
alpha was 0.87 (Si et al. 2004). The relia-
bility and validity for the present study was 
good: the scale explained 49% of the total 
variance. The reliability for the scale was 
also good with Chrobach’s alphas of 0.72 
for the total scale, and 0.67, 0.71, 0.65, 
0.45, and 0.72 for positive symptoms, neg-
ative symptoms, disorganization symp-
toms, excitement and emotional distress 
respectively.  
Insight 
Insight was assessed using the Schedule for 
Assessing Insight (SAI) (David 1990). SAI 
comprises of questions to assess three di-
mensions of insight: awareness, relabeling 
of symptoms, and attitudes to treatment. 
SAI was translated into Chinese and back-
translated into English to ensure the accu-
racy of the translation. The SAI includes 
seven items, each of which is scored on a 
three point Likert scale from 0 (no insight) 
to 2 (good insight). The range of total 
scores is from 0 to 14. For this study, the 
internal consistency of the scale was high, 
with Cronbach’s alpha of 0.89 for the total 
scale, and 0.65, 0.80, and 0.53 for aware-
ness, relabeling of symptoms and attitudes 
to treatment dimensions respectively. The 
test-retest reliability scores were 0.74, 0.44 
and 0.79 for the three dimensions. 
Social functioning  
Social functioning was rated using the Per-
sonal and Social Performance Scale (PSP) 
(Morosini et al. 2000). PSP is reliable and 
well established, based on the most recent 
version of the DSM-IV Social and Occupa-
tional Functioning Assessment Scale (SO-
FAS). PSP assesses routine social function-
ing in schizophrenia(Tianmei et al. 2011). 
The Chinese version of PSP was used for 
this study (Si et al. 2011). The PSP is a 
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100-point single-item rating scale derived 
from four functioning areas of patients with 
schizophrenia: (1) participation in social 
activities; (2) personal and social relations; 
(3) self-care; (4) interruptive or aggressive 
behaviour. Each functioning area is rated 
on a six-point Likert scale based on the de-
gree of difficulties ranging from 0 (absence 
of difficulty) to 6 (severe difficulty). The 
overall rating system of 100-points is cal-
culated based on the degree of difficulty 
across the four functioning areas. The scor-
ing ranges from 0 to 100 with a lower score 
indicating a lower level of social function-
ing. Trained mental health professionals 
interviewed patients and the family mem-
bers or carers who lived with or cared for 
the patients. 
The raters were trained in the use of 
the above assessment instruments and were 
responsible for conducting face-to-face in-
terviews with the participants. The five in-
dependent trained raters were blind to the 
allocation status of the participants. The 
intra-class correlation coefficients of all of 
the PANSS, SAI, and PSP scales in this 
study were above 0.85 after training and 
before commencement of the study. All the 
raters were retrained in the use of the as-
sessment scales bi-monthly to prevent 
rater’s drift. Assessments were done at 
baseline, week 12, week 24 (post-therapy), 
week 36, week 60 and week 84.  
 
Statistical analysis 
Analysis of the outcome measures fol-
lowed an intention to treat framework im-
plementing linear mixed models. The six 
time periods were treated as a six-level re-
peated measure in the analysis. Age was 
found to be a confounding factor (Table 1) 
and was controlled in all mixed models. 
Mixed models produce a fitted mean (in-
tercept) for the reference level of each fac-
tor in the analysis (for these analyses, the 
reference treatment group being CBT and 
the reference time point being the baseline 
measures). The mixed model analyses also 
calculated the estimates of the effect of 
each factor or a combination of factors on 
the intercept. Main effects of treatment 
group and time point and the interaction 
between treatment group and time point 
were also estimated. A significant treatment 
group by time interaction of 84 weeks sup-
ports the hypothesis that after 84 weeks, 
there is a significant difference in the ob-
served outcome measures between the two 
treatment groups. Differences in demo-
graphic characteristics between the groups 
were determined by examining 95% Con-
fidence Intervals for the difference in 
means or proportions according to the dis-
tribution of the dependent variable. All 
tests were two-tailed with alpha set at 0.05. 
A 25% or greater improvement in scores of 
PANSS, SAI and PSP between baseline 
and endpoint was identified and used to 
support a clinically significant change 
(CSC). Within groups, effect sizes are ad-
justed for correlation between means.  
 
Results 
Sample characteristics 
Ninety six patients were recruited to each 
arm of the trial. Table 1 shows compari-
sons of the demographic characteristics of 
the two groups. The groups were evenly 
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matched in terms of demographics, with 
the exception of age. The ST group was 
significantly older (mean age – 33.44 
years) than the CBT group (mean age – 
29.27 years). Age was therefore treated as 
a confounding factor in subsequent anal-
yses. 
Eighty five participants (88.5%) in the 
CBT group and 82 participants (85.4%) in 
the ST group completed the 84-week study 
block. There was no significant difference 
between treatment groups in the proportion 
of participants failing to complete assess-
ment at any individual time point. The ma-
jority of participants who dropped out of 
the study did so directly after their baseline 
assessment (n=22, 88%). Twelve (6 in each 
group) of these participants completed 
more than 6 treatment sessions before dis-
continuing treatment. The remaining 10 (4 
in CBT group and 6 in ST group) partici-
pants failed to be engaged in treatment and 
completed a mean number of 3 CBT or ST 
sessions. There was no significant differ-
ence in demographic characteristics be-
tween the treatment groups among those 
participants who failed to complete the 
study. The reasons for missing or with-
drawing included wanting “new type” CBT 
psychotherapy after being allocated to ST; 
reporting a significant improvement after 
therapy and therefore deciding to stop ther-
apy; expressing a dislike of the idea of do-
ing homework; showing discouragement 
about the lack of rapid improvement; being 
unwilling to self-disclose his or her prob-
lems; and having moved to other cities or 
going back to work or school. 
 
 [INSERT Table 1] 
 
Outcome Measures 
There were no differences in antipsychotic 
medication use at baseline to week 84, both 
in type and dosage of chlorpromazine 
equivalents. The CBT group took a 349 to 
360 mg/day equivalent of chlorpromazine, 
and the control group took a 313 to 321 
mg/day equivalent of chlorpromazine from 
baseline to 84 weeks (see Table 2). There 
was also no significant difference in the 
number of patients who changed medica-
tions or dosages during the trial period. On 
average, CBT group patients spent 40.43 
(SD 1.95) minutes per session over the 
course of treatment, and each SP group pa-
tient spent 40.06 minutes (SD, 0.83) per 
session. The CBT and ST groups did not 
differ significantly in total psychotherapy 
time or number of sessions received. Re-
duction in scores over time was observed 
in both CBT and SP groups in all of the 
outcome measures, with the exception of 
SAI and PSP in which a score increase 
over time was observed in both treatment 
groups (Table 3). The significant effect 
measured by effect size occurred from 12 
weeks and after for all measures of PANSS 
when a comparison was made between 
CBT and SP group from baseline to week 
84; although, the statistical significance 
became apparent from 36 weeks to 84 
weeks. CBT patients improved to a greater 
extent than the SP group over time, starting 
from week 36, and in all measures of 
PANSS, PSP and SAI (See Table 4).  
 
The mean PANSS total scores decreased 
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significantly over time in both treatment 
groups [CBT mean change 25.86 points 
(36.01%, SD=17.26), within groups Co-
hen’s d=1.51, ST mean change 19.04 
points (26.71%, SD=14.89), Cohen’s d= 
1.30]. The mixed model interaction term 
for treatment groups was 24 weeks and the 
following times were significant (p=0.045, 
Table 3), showing that the CBT group had 
a significantly lower PANSS total score 
after 24 weeks compared to the ST group 
(adjusted CBT mean of 46.70, SD=12.33; 
adjusted ST mean of 52.91, SD=13.43, be-
tween groups Cohen’s d=0.48). Fig. 2 
shows the mean PANSS total scores by 
treatment groups at each time point. 
A significant decrease in PANSS posi-
tive and negative symptoms was observed 
in both groups. For PANSS positive symp-
toms, the results were: CBT mean change 
10.51 points (44.83%, SD=7.79), within 
groups Cohen’s d=1.36, ST mean change 
7.44 points (33.19%, SD=7.17), d=1.1. For 
PANSS negative symptoms, the results 
were: a CBT mean change of 5.85 points 
(29.92%, SD=6.71); within the groups, 
Cohen’s d=0.83, and ST mean change was 
4.57 points (21.92%, SD=6.15), d=0.74. 
 The interaction term of 84 weeks 
for the treatment group was significant for 
the positive symptoms (whereby p=0.018, 
Table 3). This demonstrates that the CBT 
group had significantly lower PANSS posi-
tive symptoms score after 84 weeks com-
pared to the ST group (adjusted CBT mean 
of 13.18, SD=5.03; adjusted ST mean of 
15.34, SD=5.26 , between groups Cohen’s 
d=0.42). The interaction term of treatment 
group at 84 weeks was not significant for 
the negative symptoms subscale and there-
fore did not support a benefit of CBT over 
ST (Fig. 3 & 4). 
There was also a significant decrease 
over time in PANSS disorganisation symp-
toms in both treatment groups: CBT mean 
change was 8.56 points (36.47%, 
SD=7.42), d=1.19; for ST the mean change 
was 5.96 points (25.43%, SD=6.32), 
d=0.92. There was no evidence of a benefit 
of CBT over ST at 84 weeks. The PANSS 
excitement subscale also showed a signifi-
cant decrease over time in both treatment 
groups: for CBT the mean change was 4.53 
points (29.98%, SD = 4.54), d=1.32; for ST 
the mean change was 3.45 points (20.73%, 
SD=4.8), d=0.69. However, there was no 
evidence at 84 weeks that CBT provided a 
benefit over ST. The PANSS emotional dis-
tress subscale decreased over time in both 
treatment groups: for CBT the mean 
change was 8.24 points (40.05%, 
SD=7.44), d=1.15; for ST the mean change 
was 6.06 points (29.65%, SD=5.64), 
d=1.40. The mixed model interaction term 
for treatment groups at 84 weeks was ap-
proaching significance (p=0.053, Table 3). 
The mean score of PANSS disorganisation 
symptoms, excitement and emotional dis-
tress decreased over time in both treatment 
groups (Fig. 5, 6, 7). 
The mean SAI total score increased 
significantly over time by an average of 
3.98 points (66.14%, SD=4.29) in the CBT 
group (within groups Cohen’s d=-0.97) and 
by 2.37 points (40.38%, SD=4.86) in the 
ST group (d=-0.51). The interaction term 
of treatment group and time at 84 weeks 
was approaching statistical significance 
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(p=0.055, Table 3), indicating further im-
provement in the SAI total score after 84 
weeks in the CBT group compared to the 
ST group. Mean SAI score by treatment 
group and time point is shown in Fig. 8. 
Over the study period, the mean PSP 
total score increased significantly by an 
average of 22.27 points (45.96%, 
SD=15.86) in the CBT group (within 
groups Cohen’s d=-1.45) and 15.89 points 
(32.01%, SD=16.31) in the ST group (d=-
0.95). The mixed model interaction term of 
treatment group at 84 weeks was signifi-
cant (p=0.037, Table 3). This showed that 
the CBT group had a significantly higher 
PSP total score after 84 weeks of treatment 
compared to the ST group. CBT group had 
am adjusted mean of 73.70, SD=13.73; the 
adjusted ST mean was 64.30, SD=15.16, 
between groups Cohen’s d=0.64. Mean 
PSP score by treatment group and time 
point is shown in Fig. 9.  
Over three quarters (65, 76.5%) of the 
CBT group made a significant clinical im-
provement, showing a 25% or more reduc-
tion in PANSS total score from the base-
line, compared with 53.70% in the ST 
group (χ2=9.35, P=0.002). 
 
Discussion  
This was the first randomised controlled 
trial using standardised cognitive-
behavioural therapy for patients with 
schizophrenia in China. The study em-
ployed key cognitive and behavioural strat-
egies that were adapted to suit this demo-
graphic of patients suffering from schizo-
phrenia in China. Compared to ST, CBT 
showed a significantly greater and more 
durable effect on PANSS total score and 
PSP and SAI from week 36. Additionally, 
more participants in the CBT group 
achieved a more significant clinical im-
provement in PANSS total score, which 
indicated that receiving CBT increased the 
probability of meaningful symptom reduc-
tion.  
The significant effect (as measured by 
the effect size shown in both CBT groups 
in most of the PANSS measures, SAI and 
PSP in 12 weeks) suggest that rapid change 
occurs in the first 12 weeks. This is con-
sistent with Drury et al., who showed that 
CBT reduced positive symptoms and im-
proved learnt insight at a faster rate during 
the first 12 weeks (Drury et al. 2000). Dru-
ry et al. also found more rapid improve-
ment in clinical recovery, as measured by 
increased insight, less dysphoria and ‘low 
level’ psychotic thinking, and less disinhi-
bition (Drury et al. 2000). This is con-
sistent with the aim of CBT (but not sup-
portive therapies) to develop new skills and 
enduring ways of coping with psychosis 
during the first 12 weeks. Cognitive and 
behavioural skills need at least 12 weeks to 
be learnt and put into practice; only then 
can the gains be consolidated. This was 
demonstrated in the follow-up stage that 
took place between weeks 24 to 84. Addi-
tionally, assigning and completing home-
work is a possible core mechanism to pro-
mote and sustain change gained during the 
first 12 weeks of CBT sessions (Kazantzis 
et al. 2010). 
This study demonstrated the superiori-
ty of CBT over ST; the former had a dura-
ble effect on overall symptoms, and posi-
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tive symptoms emerged after the comple-
tion of therapy in week 36. This is con-
sistent with findings in similar studies in 
the UK, in which there were positive bene-
fits of both ST and CBT but the CBT con-
tinued to show improvements whereas the 
ST began to lose effectiveness after it had 
been discontinued (Sensky et al. 
2000). Our findings, showing an improve-
ment in overall and positive symptoms dur-
ing the course of treatment in the CBT 
group, are in line with Tarrier et al (Tarrier 
et al. 1998).  These researchers found sig-
nificant improvements in the severity and 
number of positive symptoms for patients 
treated with CBT(Tarrier et al. 1998). This 
was also in accordance with Zimmermann 
et al.’s meta-analysis (Zimmermann et al. 
2005). This study concluded that CBT is a 
promising adjunctive treatment for positive 
symptoms in schizophrenia spectrum dis-
orders. The positive effect of CBT in re-
ducing positive symptoms may be due to 
both non-specific and specific factors of 
CBT, such as therapeutic alliance, normali-
sation, the psychotic experience, modifica-
tion of dysfunctional cognitions and behav-
iours (Warman and Beck 2003) by examin-
ing the evidence, compensating for reason-
ing biases by using disconfirmation strate-
gies, and developing rational explana-
tions(Kuipers et al. 2006). Furthermore, 
building coping strategies is one of the 
most valuable CBT methods for helping 
people manage psychotic symptoms 
(Kingdon and Turkington 2008). 
This study also showed that CBT 
could significantly improve social func-
tioning in people with schizophrenia. CBT 
teaches or enhances personal coping strate-
gies that allow patients to manage their 
symptoms and daily hassles more effec-
tively. To support the contention that the 
above mechanisms lead to clinical im-
provement, Grant et al. proposed that these 
CBT techniques can trigger a cycle of func-
tional recovery because dysfunctional ‘self-
defeating’ beliefs or behaviours may inhibit 
a patient’s active engagement in construc-
tive activities (Grant et al. 2012). 
Compared to ST, CBT failed to 
demonstrate statistical superiority in nega-
tive symptoms, disorganisation symptoms 
and excitement; however, it approached 
significance in reducing emotional distress. 
Alternative approaches may be required for 
these symptoms that may be influenced 
more by biological and cognitive dysfunc-
tions.36 Alternatively, research studies have 
compared the effectiveness of CBT with 
that of ST for psychosis and proposed that 
ST has important but non-trivial effects on 
a variety of clinical outcomes (Penn et al. 
2004; Penn et al. 2009). Furthermore, psy-
chotherapy might assist persons to recover 
by helping them develop more complex 
ideas about themselves and others and not 
just by correct discrete dysfunctional cog-
nitions (Lysaker et al. 2010). 
This study integrated Chinese cultural 
values and practices into the use of CBT. 
For example, the more hierarchical ap-
proach to the doctor-patient relationship 
could be geared to the therapist’s advantage 
in the early phase of engagement in CBT. 
However, the emphasis then needed to shift 
to a more collaborative relationship, with 
encouragement of the patient contributing 
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to the therapy.39 Higher levels of employ-
ment were seen in the patient group, as a 
whole, which was possibly due to financial 
pressures. In Chinese culture, family mem-
bers play an important role in providing 
care, and offering support for returning to 
or maintaining employment. Therefore, 
expectations are raised (Naeem and 
Kingdon 2011). These cultural factors 
could have a mixed effect on a patient, but 
could also have enhanced social skills 
training and coping strategies enhancement 
in the CBT group. Family members were 
actively encouraged to participate in the 
therapy and help patients (although formal 
family work was not part of the interven-
tion). This study also differed from patient 
presentation in Western studies, for exam-
ple: the virtual absence of stimulant and 
cannabis misuse in the patient group. 
The study had a number of limitations. 
Although peers or specialists supervised 
the therapists regularly, the competence of 
the CBT therapists was not assessed with 
taped sessions and objective scales. How-
ever, all trial therapists were experienced 
psychiatrists or psychologists who have 
received substantial amounts of training in 
CBT by recognised experts in the field and 
have passed the criterion level of compe-
tence before commencing the trial. Fur-
thermore, the absence of a treatment-as-
usual arm did not rule out the benefits of 
CBT and ST being attributed to spontane-
ous remission with time.38 However, the 
specific benefit of CBT over ST in sustain-
ing improvement in various outcome 
measures suggests a unique advantage of 
CBT over ST. Moreover, the findings of the 
current study are demonstrably more effec-
tive than TAU in both Western and native 
researches studies (Kumari et al. 2011; 
Rector and Beck 2012; Wykes et al. 2008; 
XU and Li 2007). 
 
Conclusion 
In comparison to the ST group, the CBT 
group showed a significant improvement in 
all measures of PANSS, PSP and insight. 
The CBT group had superior effects to SP 
in positive symptoms and total scores of 
the PANSS, as well as a significant im-
provement in social functioning as assessed 
by the PSP. CBT is a useful adjunct treat-
ment to medication, with a durable effect at 
follow-up in people with schizophrenia in 
China. 
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Table 1: Comparison of demographic data between treatment groups 
Characteristics CBT ST 95% CI 
 N Mean SD N Mean SD Diff in means 
Age, y 96 29.27 8.36 96 33.44 9.51 1.62 to 6.72  
Education, y 96 13.21 2.61 96 13.21 2.65 -0.75 to 0.75  
Duration of schizophrenia, months 96 91.18 77.88 96 105.89 96.87 -39.73 to 10.31 
No of hospital admissions 96 1.69 1.79  96 1.89  1.70   -0.70 to 0.30 
Chlorpromazine equivalents at Baseline, 
mean, mg 
96 340.23 185.29 96 344.87 160.22 -54.52 to 45.25 
Psychotherapy duration, minutes 85 602.47 19.77 82 598.90 15.60 -1.89 to 9.02 
 N %  N %  Diff in proportions 
% Han ethnic group 93 96.9  93 96.9  -4.9% to 4.9% 
% Male 32 33.3  40 41.7  -21.9% to 5.3% 
% Single 70 72.9  58 60.4  -0.7% to 25.7% 
% Unemployed 42 43.8  51 53.1  -23.5% to 4.7% 
% Atypical antipsychotic medication 84 87.5  89 92.7  -0.4% to 1.7% 
CI: Confidence interval. 
 
 
 
 
Table 2 
chlorpromazine dosage use 
 
Variables CBT Control t p 
Chlorpromazine use at baseline 360.60(186.07) 321.53(169.22) 1.542 .125 
Chlorpromazine use at 12 weeks 349.80 (187.48) 313.37(158.23) 1.376 .171 
Chlorpromazine use at 24 weeks 356.08 (188.31) 318.65(167.23) 1.369 .173 
Chlorpromazine use at 36 weeks 351.88(188.3)) 316.46(166/.85) 1.289 .199 
Chlorpromazine use at 60 weeks 349.68(188.03) 316.46(166.85) 1.210 .228 
Chlorpromazine use at 84 weeks 351.32 (188.14) 315.63 (168.34) 1.289 .199 
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Table 3 Assessment of CBT and ST groups (Mean, SD, 95% CI) during the intervention and follow-up period 
Assessment 
 Mean, SD (95% CI) 
Change 0-84 weeks 
Mean, SD, % change Baseline Week 12 
Effect 
size 
Week 24 Week 36 Week 60 Week 84 
PANSS_ total         
CBT 
73.00, 13.04 
(70.36-75.64) 
57.03, 13.08 
(54.23-59.83)  
1.22 51.32, 13.25 
(48.44-54.20) 
48.79, 12.52* 
(46.04-51.54) 
48.99, 12.84** 
(46.19-51.79) 
46.71,  13.12** 
(43.85-49.57) 
25.86, 17.26, 36.01% 
ST 
72.19, 11.02 
(69.96-74.42) 
58.39, 11.92 
(55.82-60.96) 
1.20 52.23, 12.65 
(49.45-55.01) 
52.88, 13.64 
(49.86-55.90) 
54.71, 14.3 
(51.57-57.85) 
52.91, 14.45 
(49.73-56.09) 
19.04, 14.89, 26.71% 
PANSS_positive         
CBT 
23.89, 5.76 
(22.72-25.06) 
17.13, 5.52 
(15.95-18.31) 
1.19 15.23, 5.78 
(13.98-16.48) 
14.17, 5.76 
(12.90-15.44) 
13.55, 5.41 
(12.37-14.73) 
13.18, 5.35 
(12.03-14.33) 
10.51, 7.79,  44.83% 
ST 
22.96, 5.01 
(21.94-23.98) 
17.34, 4.82 
(16.30-18.38) 
1.14 15.04, 5.12 
(13.92-16.16) 
15.37, 5.32 
(14.19-16.55) 
15.67, 5.02 
(14.57-16.77) 
15.34, 5.67 
(14.09-16.59) 
7.44, 7.17, 33.19% 
PANSS_negative         
CBT 
19.99,  5.96 
(18.78-21.20) 
16.66, 5.44 
(15.49-17.83) 
0.58 15.51, 5.66 
(14.28-16.74) 
15.01, 5.58 
(13.78-16.24) 
15.67, 5.75 
(14.41-16.93) 
14.01, 5.18 
(12.89-15.13) 
5.85, 6.71, 29.91% 
ST 
20.80, 5.66 
(19.65-21.95) 
17.99, 5.35 
(16.83-19.14) 
0.51 16.45, 5.63 
(15.21-17.69) 
16.42, 5.80 
(15.14-17.70) 
17.21, 6.20 
(15.85-18.57) 
16.24, 6.45 
(14.82-17.66) 
4.57, 6.15, 21.92% 
PANSS_Disorganization         
CBT 
23.69, 6.23 
(22.43-24.95) 
18.81, 4.80 
(17.78-19.84) 
0.88 16.92, 4.55 
(15.93-17.91) 
16.27, 4.31 
(15.32-17.22) 
15.36, 3.95 
(14.50-16.22) 
15.05, 4.14 
(14.16-15.94) 
8.56, 7.42, 36.47% 
ST 
22.93, 5.62 
(21.79-24.07) 
18.95, 5.22 
(17.82-20.08) 
0.73 17.05, 4.47 
(16.07-18.03) 
17.04, 4.53 
(16.03-18.04) 
17.38, 4.48 
(16.40-18.36) 
17.10, 4.73 
(16.06-18.14) 
5.96, 6.32, 25.43% 
PANSS_Excitement         
CBT 
16.28, 3.72 
(15.53-17.03) 
12.93, 3.69 
(12.14-13.72) 
0.90 11.77, 3.72 
(10.96-12.58) 
11.45, 3.21 
(10.83-12.25) 
12.05, 3.66 
(11.25-12.84) 
11.40, 3.35 
(10.68-12.12) 
4.53, 4.54, 29.98% 
ST 
16.55, 3.82 
(15.78-17.32) 
13.49, 3.18 
(12.114-13.72) 
0.87 12.51, 3.59 
(11.72-13.30) 
12.81, 4.04 
(11.92-13.70) 
13.24, 4.62 
(12.22-14.26) 
13.12, 4.24 
(12.19-14.05) 
3.45, 4.80, 20.73% 
 PANSS_Emotional         
CBT 
20.90, 6.13 
(19.66-22.14) 
15.41, 4.90 
(14.36-16.46) 
  1.0 13.44, 4.17 
(12.54-14.34) 
12.82, 4.21 
(11.89-13.74) 
13.10, 4.18 
(12.19-14.01) 
12.53, 4.18 
(11.62-13.43) 
8.24, 7.44, 40.05% 
ST 
20.20, 4.74 
(19.24-21.16) 
15.71, 4.40 
(14.76-16.66) 
0.98 13.70, 4.12 
(12.79-14.61) 
14.09, 4.73 
(13.04-15.14) 
14.61, 4.31 
(13.66-15.56) 
14.21, 4.52 
(13.22-15.20) 
6.06, 5.64, 29.65% 
SAI         
CBT 
6.22, 3.85 
 (5.44-7.00) 
8.80, 3.74 
 (8.00-9.60) 
 0.68 
  
9.82, 3.67 
(9.02-10.62) 
10.05, 3.65 
 (9.25-10.85)  
10.17, 3.65 
 (9.37-10.97) 
10.38, 3.67 
 (9.58-11.17) 
3.98, 4.29, 66.14% 
ST 6.29, 4.25 8.22, 3.90  0.47 8.91, 4.03 8.78, 4.02 8.71, 3.99 8.83, 4.08 2.37, 4.86, 40.38% 
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(5.43-7.15) (7.38-9.06) (8.02-9.80)  (7.89-9.67)  (7.83-9.59) (7.93-9.73) 
PSP         
CBT 
50.48, 12.85  
(47.88-53.08) 
61.99, 12.91 
 (59.22-64.76) 
 0.89 66.96, 11.04 
 (64.56-69.36) 
70.35, 13.6 
 (67.34-73.36) 
71.54, 13.97 
 (68.49-74.59) 
73.68, 14.6 
 (70.53-76.83) 
22.27, 15.86, 45.96% 
ST 
48.73, 13.42 
 (46.13-51.33) 
58.33, 13.24  
(55.47-61.19) 
 0.72 63.68, 13.56 
 (60.70-66.66) 
63.63, 15.77 
 (60.14-67.12) 
62.39, 15.87 
 (58.90-65.88) 
64.33, 16.36 
 (60.74-67.92) 
15.89, 16.31, 32.01% 
PANSS: Positive and Negative Syndrome Scale; SAI: Schedule for Assessing Insight; PSP: Personal and Social Performance Scale; NS: non significant; CI: Confidence interval. 
 
 
 
 
 
 
 
 
 
Table 4 
Difference between CBT and SP group in PANSS, insight and PSP scores from baseline to 84 weeks assessment 
 
Variables Control 
(n=90) 
CBT 
(n-87) 
T p Effect size 
PANSS baseline 72.77(10.90) 72.92(13.03) -0.072 0.943 0.01 
PANSS 12 weeks 58.84(11.60) 57.01(13.15) 0.948 0.345 0.15 
PANSS 24 weeks 52.53(12.79) 51.30(13.33) 0.6 0.549 0.10 
PANSS 36 weeks 53.09(13.69) 48.75(12.60) 2.074 0.04 0.33 
PANSS 60 weeks 54.86(14.46) 49.05(12.91) 2.684 0.008 0.42 
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PANSS 84 weeks 53.00(14.60) 46.75(13.19) 2.863 0.005 0.45 
PSP baseline 47.40(13.11) 51.09(12.46) -1.918 0.057 0.29 
PSP 12 weeks 58.01(13.37) 62.06(12.97) -1.979 0.049 0.31 
PSP 24 weeks 63.51(13.87) 67.05(11.08) -1.792 0.075 0.28 
PSP 36 weeks 63.36(16.11) 70.48(13.73) -3.004 0.003   0.48 
PSP 60 weeks 62.17(16.22) 71.68(14.00) -3.979 <0.001 0.63 
PSP 84 weeks 64.12(16.72) 73.85(14.61) -3.946 <0.001   0.62 
Insight baseline 6.08(4.06) 6.36(3.83) -0.464 0.643 0.07 
Insight 12 weeks 8.18(3.90) 8.86(3.73) -1.137 0.257 0.18 
Insight 24 weeks 8.83(4.07) 9.89(3.64) -1.741 0.084 0.28 
Insight 36 weeks 8.77(4.03) 10.12(3.61) -2.232 0.027 0.35 
Insight 60 weeks 8.65(3.98) 10.24(3.61) -2.653 0.009 0.42 
Insight 84 weeks 8.78(4.07) 10.44(3.65) -2.735 0.007 0.43 
 Notes. Statistical significance: p <0.05;  Effect size: 1.0-1.90 small effect size, 0.20 to 0.39 moderate level 
 Effect size, 0.40 and more: big effect size.  
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Table 5: Mixed models analysis of outcome measures  
Outcome Measure 
84 weeks 
PANSS 
total 
PANSS positive PANSS negative 
PANSS disor-
ganization 
PANSS excite-
ment 
PANSS emo-
tional 
SAI PSP 
Parameter Estimate -5.60 -2.80 -0.94 -2.02 -1.32 -2.07 1.63 6.57 
95% CI  -11.09 to 0.11  -5.13 to -0.47 -1.54 to 3.42 -4.21 to 0.16  -2.94 to 0.30 -4.16 to 0.03 -0.04 to 3.30 0.41 to 12.73 
t t325 = 2.01 t344 = 2.37 - - - t350 = 1.94 t349 = -1.92 T324= -2.10 
P 0.045 0.018 NS NS NS 0.053 0.055 0.037 
PANSS: Positive and Negative Syndrome Scale; SAI: Schedule for Assessing Insight; PSP: Personal and Social Performance Scale; NS: non significant; CI: Confidence interval. 
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96 Allocated to CBT group  
96 at baseline 
96 Allocated to ST group 
96 at baseline 
24 week (n=96) 
84 assessed 
12 missed or withdrew 
60 week (n=96) 
83 assessed 
13 missed or withdrew 
60 week (n=96) 
81 assessed 
15 missed or withdrew 
24 week (n=96) 
81 assessed 
15 missed or withdrew 
36 week (n=96) 
82 assessed 
14 missed or withdrew 
36 week (n=96) 
80 assessed 
16 missed or withdrew 
84 week (n=96) 
85 assessed 
11 missed or withdrew 
84 week (n=96) 
82 assessed 
14 missed or withdrew 
12 week (n=96) 
 86 assessed 
10 missed or withdrew 
12 week (n=96) 
84 assessed 
12 missed or withdrew 
Contacted participants (n=280) 
Baseline completed (n=243) 
Excluded (n=51) 
39 Did not meet inclusion criteria  
12 Unable to randomize 
4 lost before randomization 
8 refused to randomization 
Excluded (n=37) 
37 Refused to participate  
Randomization (n=192) 
Figure 1. CONSORT diagram. CBT: Cognitive-Behavioural Therapy, ST: Supportive Therapy 
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Figure 2: Mean (SE) PANSS total score by time point.  
Baseline means are raw means, all other means are adjusted to include values from the mixed models 
 
 
 
Figure 3: Mean (SE) PANSS positive symptoms score by time point.  
Baseline means are raw means, all other means are adjusted to include values from the mixed models 
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Figure 4: Mean (SE) PANSS negative symptoms score by time point.  
Baseline means are raw means, all other means are adjusted to include values from the mixed models 
 
 
 
 
Figure 5: Mean (SE) PANSS disorganization symtoms score by time point.  
Baseline means are raw means, all other means are adjusted to include values from the mixed models 
 
0
5
10
15
20
25
0 12 24 36 60 84
Time Point (weeks)
M
e
a
n
 P
A
N
S
S
 n
e
g
a
ti
v
e
 s
y
m
p
to
m
s
 s
c
o
re
CBT total ST total
0
5
10
15
20
25
30
0 12 24 36 60 84
Time Point (weeks)
M
e
a
n
 P
A
N
S
S
 d
is
o
rg
a
n
iz
a
ti
o
n
 s
y
m
p
to
m
s
 s
c
o
re
CBT total ST total
28 
 
 
Figure 6: Mean (SE) PANSS excitement score by time point.  
Baseline means are raw means, all other means are adjusted to include values from the mixed models 
 
 
Figure 7: Mean (SE) PANSS emotional distress score by time point.  
Baseline means are raw means, all other means are adjusted to include values from the mixed models 
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Figure 8: Mean (SE) SAI total score by time point.  
Baseline means are raw means, all other means are adjusted to include values from the mixed models 
 
 
 
Figure 9: Mean (SE) PSP total score by time point.  
Baseline means are raw means, all other means are adjusted to include values from the mixed models 
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